Expertise in
10
conditions

Dr. Nirmish R. Shah

Duke Health Integrated Practice Inc
Durham, NC
Expertise in
10
conditions
Specialties:Pediatrics | Hematology | Oncology
Accepting New Patients
Offers Telehealth
Expertise in
10
conditions
OverviewInsuranceLocationsClinical Research

Overview

Nirmish Shah is a Pediatrics specialist and a Hematologist in Durham, North Carolina. Dr. Shah is highly rated in 10 conditions, according to our data. His top areas of expertise are Sickle Cell Disease, Hemoglobinopathy, Congenital Hemolytic Anemia, Hemolytic Anemia, and Bone Marrow Transplant. Dr. Shah is currently accepting new patients.

His clinical research consists of co-authoring 122 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Pediatrics
Hematology
Oncology
Licenses
Internal Medicine in NC
Hospital Affiliations
Duke University Hospital
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Cigna
  •  Blue Cross Blue Shield
  •  UnitedHealthcare
  •  Humana
  •  Piedmont

Locations

DUKE HEALTH INTEGRATED PRACTICE INC
40 Duke Medicine Cir, Durham, NC 27710
919-684-8111
Other Locations
DUKE HEALTH INTEGRATED PRACTICE INC
2351 Erwin Rd, Durham, NC 27705
919-684-8111
DUKE HEALTH INTEGRATED PRACTICE INC
2301 Erwin Rd, Durham, NC 27705
919-684-8111

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

A Randomized, Double-blind, Placebo-controlled, Multicenter Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive Crises
A Randomized, Double-blind, Placebo-controlled, Multicenter Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive Crises
Enrollment Status: Terminated
Publish Date: December 11, 2024
Intervention Type: Drug
Study Drug: Inclacumab
Study Phase: Phase 3
An Open Label, Observational, Prospective Registry of Participants With Sickle Cell Disease (SCD) Treated With Oxbryta® (Voxelotor)
An Open Label, Observational, Prospective Registry of Participants With Sickle Cell Disease (SCD) Treated With Oxbryta® (Voxelotor)
Enrollment Status: Terminated
Publish Date: November 25, 2024
Intervention Type: Drug
A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Inclacumab in Participants With Sickle Cell Disease Experiencing Vaso-occlusive Crises
A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Inclacumab in Participants With Sickle Cell Disease Experiencing Vaso-occlusive Crises
Enrollment Status: Completed
Publish Date: November 18, 2024
Intervention Type: Drug
Study Drug: Inclacumab
Study Phase: Phase 3
A Phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (Crizanlizumab), With or Without Hydroxyurea/Hydroxycarbamide, in Sickle Cell Patients With Vaso-Occlusive Crisis
A Phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (Crizanlizumab), With or Without Hydroxyurea/Hydroxycarbamide, in Sickle Cell Patients With Vaso-Occlusive Crisis
Enrollment Status: Completed
Publish Date: October 09, 2024
Intervention Type: Drug
Study Drug: Crizanlizumab
Study Phase: Phase 2
Patient-Empowered Mobile Technology in Hospitalized Patients: Technology Resources to Understand Pain Assessment in Patients With Pain (TRU-PAIN)
Patient-Empowered Mobile Technology in Hospitalized Patients: Technology Resources to Understand Pain Assessment in Patients With Pain (TRU-PAIN)
Enrollment Status: Completed
Publish Date: May 23, 2024
Intervention Type: Other
Study Phase: Not Applicable
A Retrospective Data Collection and Analysis Study of Patients With Sickle Cell Disease (SCD) Who Have Been Treated With Oxbryta® (Voxelotor)
A Retrospective Data Collection and Analysis Study of Patients With Sickle Cell Disease (SCD) Who Have Been Treated With Oxbryta® (Voxelotor)
Enrollment Status: Completed
Publish Date: March 06, 2024
Intervention Type: Drug
Integration of mHEALTH Into the Care of Patients With Sickle Cell Disease to Increase Hydroxyurea Utilization- mESH Study
Integration of mHEALTH Into the Care of Patients With Sickle Cell Disease to Increase Hydroxyurea Utilization- mESH Study
Enrollment Status: Completed
Publish Date: November 29, 2023
Intervention Type: Behavioral
Study Phase: Not Applicable
A Phase 4, Multicenter, Open-label Study to Evaluate the Treatment Effect of Voxelotor on Physical Activity in Adolescents and Adults With Sickle Cell Disease
A Phase 4, Multicenter, Open-label Study to Evaluate the Treatment Effect of Voxelotor on Physical Activity in Adolescents and Adults With Sickle Cell Disease
Enrollment Status: Completed
Publish Date: November 21, 2023
Intervention Type: Drug
Study Drug: Voxelotor
Study Phase: Phase 4
Early Low-dose Ketamine Infusion Versus Usual Care for Sickle Cell Pain Crisis: a Randomized, Prospective Study.
Early Low-dose Ketamine Infusion Versus Usual Care for Sickle Cell Pain Crisis: a Randomized, Prospective Study.
Enrollment Status: Withdrawn
Publish Date: January 14, 2022
Intervention Type: Drug, Other
Study Phase: Phase 4
Adjuvant Low Dose Rituximab for Acquired TTP With Severe ADAMTS13 Deficiency
Adjuvant Low Dose Rituximab for Acquired TTP With Severe ADAMTS13 Deficiency
Enrollment Status: Completed
Publish Date: August 17, 2021
Intervention Type: Biological
Study Phase: Phase 2
Use of a Mobile-based Pain Assessment Application for SCD Patients
Use of a Mobile-based Pain Assessment Application for SCD Patients
Enrollment Status: Completed
Publish Date: July 16, 2019
Use of Mobile Technology for Intensive Training in Medication Management
Use of Mobile Technology for Intensive Training in Medication Management
Enrollment Status: Completed
Publish Date: May 25, 2017
Intervention Type: Behavioral
Study Phase: Not Applicable
View 11 Less Clinical Trials

122 Total Publications

Empowering youth as Changemakers for gender-transformative action: a play-based participatory approach in South-East Nepal.
Empowering youth as Changemakers for gender-transformative action: a play-based participatory approach in South-East Nepal.
Journal: Perspectives in public health
Published: October 14, 2024
Similar Doctors
Expertise in
7
conditions
Dr. Marilyn J. Telen
Hematology | Oncology
Expertise in
7
conditions
Dr. Marilyn J. Telen
Hematology | Oncology

Duke Health Integrated Practice Inc

40 Duke Medicine Cir, 
Durham, NC 
919-684-8111
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Marilyn Telen is a Hematologist and an Oncologist in Durham, North Carolina. Dr. Telen is highly rated in 7 conditions, according to our data. Her top areas of expertise are Sickle Cell Disease, Congenital Hemolytic Anemia, Hemoglobinopathy, and Hemolytic Anemia. Dr. Telen is currently accepting new patients.

Expertise in
18
conditions
Dr. Deborah M. Stephens
Hematology | Oncology | Hematology Oncology
Expertise in
18
conditions
Dr. Deborah M. Stephens
Hematology | Oncology | Hematology Oncology

University Of North Carolina At Chapel Hill

101 Manning Dr, 
Chapel Hill, NC 
 (9.5 mi)
984-974-1000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Deborah Stephens is a Hematologist and an Oncologist in Chapel Hill, North Carolina. Dr. Stephens is highly rated in 18 conditions, according to our data. Her top areas of expertise are Chronic B-Cell Leukemia (CBCL), Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Stephens is currently accepting new patients.

Expertise in
18
conditions
Dr. Henry S. Friedman
Neurosurgery | Hematology Oncology | Hematology
Expertise in
18
conditions
Dr. Henry S. Friedman
Neurosurgery | Hematology Oncology | Hematology

Duke Health Integrated Practice Inc

40 Duke Medicine Cir, 
Durham, NC 
919-684-8111
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Henry Friedman is a Neurosurgery specialist and a Hematologist Oncology provider in Durham, North Carolina. Dr. Friedman is highly rated in 18 conditions, according to our data. His top areas of expertise are Glioma, Astrocytoma, Glioblastoma, and Brain Tumor. Dr. Friedman is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile